| 2026-09-11 16:51 |
8-K |
["5.07"] |
other |
0.00
|
8-K/A amendment reporting shareholder advisory vote on executive compensation frequency; no M&A signals. |
SEC · detail |
| 2026-08-28 17:08 |
8-K |
["7.01"] |
other |
0.15
|
8-K reports delay in Phase 2 trial data presentation; forward-looking statements mention 'strategic transaction' but provide no M&A details. |
SEC · detail |
| 2026-08-04 17:20 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine earnings release filing with no M&A signals, strategic review language, or transaction indicators. |
SEC · detail |
| 2026-07-13 17:28 |
8-K |
["8.01"] |
other |
0.15
|
Special dividend and share repurchase following completed asset sale to Apotex; no M&A signal. |
SEC · detail |
| 2026-07-01 16:15 |
8-K |
["1.01", "1.02", "2.01", "5.02", "8.01"] |
merger agreement |
0.95
|
Cumberland Pharmaceuticals completed asset sale to Nuvo/Apotex for $100M on July 1, 2026. |
SEC · detail |
| 2026-06-25 17:00 |
8-K |
["5.07"] |
merger agreement |
0.98
|
Cumberland shareholders approved asset purchase with Apotex affiliate; sale of substantially all FDA-approved commercial products. |
SEC · detail |
| 2026-05-26 06:00 |
DEFM14A |
|
merger agreement |
0.98
|
DEFM14A proxy filing for definitive asset purchase agreement between Cumberland Pharmaceuticals and Apotex for $100M cash. |
SEC · detail |
| 2026-05-15 16:27 |
PREM14A |
|
merger agreement |
0.98
|
PREM14A filed for shareholder vote on asset purchase agreement with Apotex for $100M sale of FDA-approved products. |
SEC · detail |
| 2026-05-05 17:07 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine Q1 2026 earnings announcement with no M&A indicators or strategic transaction language. |
SEC · detail |
| 2026-04-24 17:08 |
8-K |
["5.07"] |
other |
0.05
|
Routine annual shareholder meeting with director elections and auditor ratification; no M&A signals. |
SEC · detail |